Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics Announces Presentations of Abstracts at the 59th ERA Congress
May 17, 2022 16:30 ET | Travere Therapeutics, Inc.
SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced presentations including baseline characteristics for patients enrolled in the ongoing pivotal...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics Reports First Quarter 2022 Financial Results
May 05, 2022 16:01 ET | Travere Therapeutics, Inc.
Submitted New Drug Application (NDA) for sparsentan in IgA nephropathy in March 2022 Results from Phase 1/2 COMPOSE Study of pegtibatinase in classical homocystinuria (HCU) presented at the Society...
Angion_2IN-02.jpg
Angion Provides Corporate Update and Reports Full Year 2021 Financial Results
March 30, 2022 16:05 ET | Angion Biomedica Corp.
-- Enrollment continues in Phase 2 JUNIPER trial of ANG-3070 for the treatment of patients with primary proteinuric kidney diseases -- Ended the year with nearly $89M in cash and cash equivalents ...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
February 24, 2022 16:01 ET | Travere Therapeutics, Inc.
NDA submission of sparsentan in IgA nephropathy on-track for first quarter 2022 Company positioned for potential NDA submission for accelerated approval of sparsentan in FSGS and combined IgA...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics Provides Corporate Update and 2022 Outlook
January 10, 2022 07:00 ET | Travere Therapeutics, Inc.
SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for...
Angion_2IN-02.jpg
Angion Presents Multiple Posters on ANG-3070 at Kidney Week 2021, Including Preclinical Data and Design of Upcoming Phase 2 Study
November 05, 2021 00:05 ET | Angion Biomedica Corp.
UNIONDALE, N.Y., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics Reports Third Quarter 2021 Financial Results and Organizational Progress
October 28, 2021 16:01 ET | Travere Therapeutics, Inc.
Recently reported positive topline interim results from the ongoing pivotal Phase 3 PROTECT Study of sparsentan in IgA nephropathy Following pre-NDA interactions with FDA, NDA submission of...
Angion_2IN-02.jpg
Angion to Present Multiple Posters at Kidney Week 2021
October 18, 2021 16:05 ET | Angion Biomedica Corp.
UNIONDALE, N.Y., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics and Vifor Pharma Announce Licensing Agreement for the Commercialization of Sparsentan in Europe, Australia and New Zealand
September 15, 2021 16:05 ET | Travere Therapeutics, Inc.
Vifor Pharma obtains exclusive commercialization rights for sparsentan in Europe, Australia and New Zealand Travere receives a $55 million upfront payment and is eligible for additional regulatory...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics Appoints Ruth Williams-Brinkley to its Board of Directors
September 14, 2021 16:30 ET | Travere Therapeutics, Inc.
SAN DIEGO, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the appointment of Ruth Williams-Brinkley to the Company’s Board of Directors, effective...